About: Inebilizumab

An Entity of Type: monoclonal antibody, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org:8891

Inebilizumab, sold under the brand name Uplizna, is a medication for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults. The most common adverse reactions include urinary tract infection, headache, joint pain (arthralgia), nausea and back pain. Inebilizumab is a humanized mAb that binds to and depletes CD19+ B cells including plasmablasts and plasma cells. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.

Property Value
dbo:abstract
  • Inebilizumab, sold under the brand name Uplizna, is a medication for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults. The most common adverse reactions include urinary tract infection, headache, joint pain (arthralgia), nausea and back pain. Inebilizumab is a humanized mAb that binds to and depletes CD19+ B cells including plasmablasts and plasma cells. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. (en)
  • イネビリズマブ（Inebilizumab）は、成人の視神経脊髄炎スペクトラム障害（NMOSD）を治療する為の医薬品である。形質細胞やプラズマ細胞を含むCD19+ B細胞に結合し、これを除去するヒト化モノクローナル抗体である。 主な副作用は、尿路感染症、頭痛、関節痛（人工関節痛）、吐き気、腰痛などである。 米国食品医薬品局（FDA）は、本薬を画期的医薬品と位置付けている。 (ja)
dbo:alternativeName
  • Uplizna (en)
dbo:casNumber
  • 1299440-37-1
dbo:class
dbo:drugbank
  • DB12530
dbo:fdaUniiCode
  • 74T7185BMM
dbo:kegg
  • D11757
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 50977311 (xsd:integer)
dbo:wikiPageLength
  • 12736 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1123986817 (xsd:integer)
dbo:wikiPageWikiLink
dbp:atcPrefix
  • L04 (en)
dbp:atcSuffix
  • AA47 (en)
dbp:c
  • 6504 (xsd:integer)
dbp:casNumber
  • 1299440 (xsd:integer)
dbp:chemspiderid
  • None (en)
dbp:class
dbp:dailymedid
  • Inebilizumab (en)
dbp:drugbank
  • DB12530 (en)
dbp:h
  • 10080 (xsd:integer)
dbp:kegg
  • D11757 (en)
dbp:legalUs
  • Rx-only (en)
dbp:mabType
  • mab (en)
dbp:n
  • 1732 (xsd:integer)
dbp:o
  • 2044 (xsd:integer)
dbp:routesOfAdministration
dbp:s
  • 44 (xsd:integer)
dbp:source
  • zu (en)
dbp:synonyms
  • MEDI-551, inebilizumab-cdon (en)
dbp:target
dbp:tradename
  • Uplizna (en)
dbp:type
  • mab (en)
dbp:unii
  • 74 (xsd:integer)
dbp:wikiPageUsesTemplate
dcterms:subject
rdf:type
rdfs:comment
  • Inebilizumab, sold under the brand name Uplizna, is a medication for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults. The most common adverse reactions include urinary tract infection, headache, joint pain (arthralgia), nausea and back pain. Inebilizumab is a humanized mAb that binds to and depletes CD19+ B cells including plasmablasts and plasma cells. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. (en)
  • イネビリズマブ（Inebilizumab）は、成人の視神経脊髄炎スペクトラム障害（NMOSD）を治療する為の医薬品である。形質細胞やプラズマ細胞を含むCD19+ B細胞に結合し、これを除去するヒト化モノクローナル抗体である。 主な副作用は、尿路感染症、頭痛、関節痛（人工関節痛）、吐き気、腰痛などである。 米国食品医薬品局（FDA）は、本薬を画期的医薬品と位置付けている。 (ja)
rdfs:label
  • Inebilizumab (en)
  • イネビリズマブ (ja)
owl:sameAs
prov:wasDerivedFrom
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is dbp:medication of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License